Kamada (KMDA) has released an update.
Kamada Ltd., a global biopharmaceutical company specializing in rare and serious conditions, is set to release its financial results for the second quarter and first half of 2024 on August 14, before the U.S. market opens. The company will also host a conference call on the same day to discuss the results and address investor queries. Kamada’s diverse portfolio includes FDA-approved plasma-derived products, with a strategic focus on growth through its commercial products and ongoing research in areas with high unmet medical needs.
For further insights into KMDA stock, check out TipRanks’ Stock Analysis page.
